摘要
cemiplimab-rwlc (Cem)是由赛诺菲和再生元制药公司共同研发的完全人源化的抑制程序性死亡受体1 (PD-1)的IgG4单克隆抗体,它能够阻断PD-1与程序性死亡配体1 (PD-L1)结合,影响PD-1/PD-L1通路的信号转导,增强T细胞的免疫杀伤功能,进而发挥抗肿瘤作用。2018年9月28日,美国食品和药物管理局批准Cem用于局部晚期或转移性皮肤鳞状细胞癌(CSCC)患者的治疗。最近的研究表明, Cem治疗局部晚期或转移性CSCC时,约半数患者可获客观缓解,而且患者肿瘤缓解的持续时间较长,具有较好的治疗效果。其常见的不良事件主要为腹泻、疲劳和恶心。
Cemiplimab-rwlc(Cem) is a fully human IgG4 monoclonal antibody that binds to programmed death 1(PD-1),which was developed by Sanofi and Regeneron Pharmaceuticals,Inc.It can block the binding of PD-1 to programmed death ligand 1(PD-L1) and affects the signal transduction of PD-1/PD-L1 pathway.It enhances the immune killing function of T cells,thereby exerting anti-tumor effects.Cem was approved for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma(CSCC) by the U.S.Food and Drug Administration on September 28,2018.Recent studies have shown that about half of patients with locally advanced or metastatic CSCC can achieve objective remission when treated with Cem,and the duration of tumor remission in patients is long and has a good therapeutic effect.The common adverse events are mainly diarrhea,fatigue and nausea.
作者
张莉
汪龙
宋佳伟
ZHANG Li;WANG Long;SONG Jia-wei(Department of Pharmacy,the Second Affiliated Hospital of Bengbu Medical College,Bengbu ANHUI 233040,China;Department of Pharmacy,the Third People's Hospital of Bengbu,Bengbu ANHUI 233099,China;Department of Pharmacy,People's Hospital of Bozhou,Bozhou ANHUI 236800,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2019年第2期70-73,共4页
Chinese Journal of New Drugs and Clinical Remedies
